Please provide your email address to receive an email when new articles are posted on . Sixty-six adults with binge-eating disorder were given either naltrexone/bupropion or placebo for 16 weeks. The combination of naltrexone and bupropion results in a response rate almost six times greater than with placebo in patients with moderate or severe methamphetamine use disorder, results of a new ...

Understanding the Context

Business Insider: NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine “Real-world data demonstrates that [naltrexone-bupropion] is as effective and safe in this population as in surgery-naive patients. Additionally, this effect was independent of dose, which could make ... FiercePharma: Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union MedPage Today: Support for Naltrexone-Bupropion for Long-term Weight Management in Selected Patients A study by Ethan Lazarus, MD, in Obesity Pillars presents a comprehensive review of the appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) for the ...